Every 8-K that Sight Sciences, Inc. (SGHT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SGHT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGHT filings page.
Sight Sciences, Inc. appointed Kashif Rashid as Chief Legal Officer and Corporate Secretary effective August 10, 2026, succeeding Jeremy Hayden, who will step down on that date and stay through August 31, 2026 to assist with transition. Rashid brings extensive legal and corporate development experience from prior roles at Nevro Corp., Atara Biotherapeutics, St. Jude Medical and General Electric’s healthcare business.
Under his employment agreement, Rashid will receive an initial annual base salary of $450,000 and will be eligible for an annual cash bonus targeted at 50% of base salary. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base-salary severance, any earned but unpaid prior-year bonus, and up to 12 months of COBRA premium support, subject to specified conditions. He is also eligible for a restricted stock unit award valued at $1,400,000, vesting in four equal annual installments starting August 10, 2027, with the number of shares based on the grant-date closing price and capped at 280,000 shares. Hayden, subject to a separation agreement and release, will receive one year of base salary and up to one year of COBRA benefits.
Sight Sciences reported strong Q2 2026 results, with revenue of $23.4 million, up 20% year-over-year, driven by 8% growth in Interventional Glaucoma to $20.7 million and a 704% surge in Interventional Dry Eye to $2.7 million. Gross margin was 91%, benefiting from $1.4 million of tariff refunds; excluding these, gross margin was 86%.
Total operating expenses fell 11% to $25.3 million and adjusted operating expenses declined 8% to $22.3 million. Net loss narrowed to $4.4 million, a 63% improvement, or $0.08 per share. Cash and cash equivalents were $79.8 million, with cash usage of $5.2 million including one-time items; excluding these, usage was $1.4 million.
Management raised 2026 guidance, now expecting revenue of $88 million to $92 million and adjusted operating expenses of $92 million to $94 million. The quarter also featured expanded payer coverage for both glaucoma and dry eye treatments and FDA 510(k) clearance for the OMNI Ultra Surgical System.
Sight Sciences, Inc. reported the results of its annual stockholder meeting held on June 4, 2026. A total of 41,456,258 shares were present or represented by proxy, which was about 76.2% of the 54,403,542 shares outstanding as of the April 8, 2026 record date.
Stockholders elected Class II directors Gerhard Burbach and Staffan Encrantz to serve until the 2029 annual meeting or until their successors are elected. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. No other matters were brought for a vote.
Sight Sciences reported first quarter 2026 revenue of $19.7 million, up 13% from a year earlier, driven by glaucoma and dry eye products. Interventional Glaucoma revenue rose to $18.3 million, while Interventional Dry Eye reached $1.4 million, a 244% year-over-year increase.
The company delivered an overall gross margin of 86% and cut quarterly cash usage to $7.0 million, ending March 31, 2026 with $85.0 million in cash and cash equivalents. Net loss narrowed to $13.0 million, or $0.24 per share.
Sight Sciences raised its full-year 2026 revenue outlook to $83.0–$89.0 million, including $77.0–$81.0 million from Interventional Glaucoma and $6.0–$8.0 million from Interventional Dry Eye. A Delaware court’s final judgment in its litigation with Alcon awarded $55.4 million in past damages and a 10% ongoing Hydrus Microstent royalty, subject to appeal.
Sight Sciences, Inc. announced that a U.S. District Court entered a Final Judgment in its patent case against Alcon, awarding the company $55.4 million in total monetary damages and confirming that the asserted patent claims are valid and were willfully infringed.
The award includes $34.0 million in past damages through April 26, 2024, $14.7 million in supplemental damages through March 31, 2026, and $6.8 million in pre‑judgment and post‑judgment interest through April 17, 2026. The judgment also grants an ongoing 10% royalty on Hydrus Microstent revenue until the last of the patents expires. However, Alcon may appeal, and Sight Sciences will not receive any monetary damages unless appeals conclude or the appeal period ends without appeal, and certain patent reexamination outcomes could affect its ability to collect.
Sight Sciences, Inc. announced that the U.S. District Court for the District of Delaware issued an order preserving a jury’s verdict that Alcon willfully infringed three Sight Sciences glaucoma patents. The order awards $34 million in past monetary damages, plus supplemental damages and interest, and grants an ongoing 10% royalty on Hydrus Microstent revenue through November 10, 2028, when the last asserted patent expires. A final judgment will be entered after supplemental damages and pre-judgment interest are calculated and remains subject to appeal by Alcon. Parallel ex parte reexaminations at the USPTO could affect Sight Sciences’ ability to collect if adverse outcomes become final before the litigation is finally resolved in the company’s favor. Sight Sciences expects to record a $5.4 million success fee payable to its litigation counsel in operating expenses, which it plans to exclude from non-GAAP adjusted operating expenses.
Sight Sciences reported mixed 2025 results with improving profitability trends and issued 2026 guidance. Full-year 2025 revenue was $77.4 million, down 3% from 2024, as Interventional Glaucoma revenue held flat at $75.7 million while Interventional Dry Eye fell to $1.6 million.
Fourth-quarter 2025 revenue was $20.4 million, up 7%, with total gross margin at 87%. Full-year gross margin was 86%. Operating expenses fell 13% to $103.8 million and net loss narrowed to $38.4 million, or $0.74 per share, from $51.5 million.
Cash and cash equivalents were $92.0 million and long-term debt $40.0 million as of December 31, 2025, after $28.4 million of cash use in 2025. For 2026, the company guides revenue to $82–$88 million and adjusted operating expenses to $93–$96 million.
Sight Sciences, Inc. entered into a Second Amendment to its multi-tenant space lease for its headquarters at 4040 Campbell Avenue, Menlo Park, California. The amendment, signed with Deerfield Campbell, LLC, extends the existing lease term by 26 months, starting on November 1, 2026 and ending on December 31, 2028.
Under the extension, base monthly rent is fully abated from November 1, 2026 through December 31, 2026. Rent is then set at $44,915.45 per month from January 1, 2027 through October 31, 2027, $46,214.21 per month from November 1, 2027 through October 31, 2028, and $47,621.20 per month from November 1, 2028 through December 31, 2028.
Sight Sciences, Inc. filed a current report to let investors know it has released preliminary, unaudited financial results. On January 13, 2026, the company issued a press release with selected results for the fourth quarter and full year ended December 31, 2025. That press release is included as Exhibit 99.1 to this Form 8-K under the section covering results of operations and financial condition. The company states that this information, including the exhibit, is being furnished rather than filed, which limits how it is treated under securities law and how it may be incorporated into other SEC filings.
Sight Sciences (SGHT) reported leadership changes and furnished Q3 updates. The company promoted Alison Bauerlein to Chief Operating Officer, effective November 5, 2025; she will serve as Principal Operating Officer and cease serving as CFO, Treasurer, Principal Financial Officer and Principal Accounting Officer.
James (Jim) Rodberg was promoted to Chief Financial Officer and Treasurer, also effective November 5, 2025, and will serve as Principal Financial and Accounting Officer. Bauerlein’s compensation includes a $485,000 base salary, a cash bonus target at 65% of salary, and RSUs valued at $150,000 vesting in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Rodberg’s terms include a $400,000 base salary, a 50% bonus target, and $100,000 in RSUs with the same vesting schedule.
Brenda Becker and Erica Rogers resigned from the Board effective November 4, 2025, stating no disagreement with the company. The Board size was reduced from nine to seven, and Catherine Mazzacco was reassigned to Class I with a term ending at the 2028 annual meeting. The company furnished an earnings press release and a leadership press release, and posted an investor presentation.
Sight Sciences announced that two Medicare Administrative Contractors, Novitas and FCSO, established jurisdiction-wide pricing for CPT 0563T, which describes the TearCare procedure. The Medicare fee schedule amount is $1,141.59, effective for dates of service on and after January 1, 2025, across all Novitas and FCSO jurisdictions.
The local fee schedules are active for claim processing and are expected to be posted on the Novitas and FCSO websites. TearCare claims in these areas will be payable based on individual medical necessity determinations. The regions covered by these MACs have an estimated 10.4 million total covered lives. The company also posted an investor presentation and plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.
Sight Sciences entered a third amendment to its senior secured term loan with Hercules Capital, which allows borrowing of up to $65.0 million in total. The amendment adds another six months to the interest-only period, which now runs until February 1, 2027, giving the company more time before it must start repaying principal.
The change also reallocates an undrawn and unavailable $10.0 million tranche so that the amount the company can draw during the interest-only period increases from $15.0 million to $25.0 million, in minimum increments of $5.0 million, subject to approval by Hercules’ investment committee. In return for these changes, Sight Sciences paid Hercules a $50,000 fee plus certain costs and expenses.
Sight Sciences is launching a restructuring plan to cut operating costs and support its path to breakeven without additional equity capital. The company will reduce headcount by 43 employees, about 20% of its global workforce, trim research and development spending, limit marketing, travel and administrative costs, and leave some open roles unfilled. It expects a cash restructuring charge of approximately $2.7 million to $3.0 million and a non-cash reduction in stock-based compensation of about $0.6 million to $1.0 million, primarily in the third quarter of 2025. The workforce plan alone is estimated to yield around $11.9 million in annualized savings. The company also announced that its Chief Commercial Officer, Matthew Link, will step down effective August 31, 2025, with his severance included in the restructuring costs. Sight Sciences reaffirmed its 2025 revenue guidance of $72.0 million to $76.0 million, reiterated that third quarter 2025 surgical glaucoma revenue is expected to be down by mid-single digits year over year, and lowered its 2025 adjusted operating expense guidance to $95 million to $99 million from $101 million to $105 million.